Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis

Cancer Science

Volumn 103, Issue 3, 2012, Pages 577-586

  Koinuma, Junkichi ^a,b   Akiyama, Hirohiko ^c   Fujita, Masahiro ^d   Hosokawa, Masao ^d   Tsuchiya, Eiju ^e   Kondo, Satoshi ^b   Nakamura, Yusuke ^a   Daigo, Yataro ^a,f  

^a UNIVERSITY OF TOKYO   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d Keiyukai Sapporo Hospital   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

^f SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; OPA INTERACTIVNG PROTEIN 5; PROTEIN; RAF PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; NONHISTONE PROTEIN; OIP5 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; DNA MICROARRAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; CANCER STAGING; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETICS; IMMUNOPRECIPITATION; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; NORTHERN BLOTTING; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859702328     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02167.x     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Shimada H, Nabeya Y, Ochiai T et al. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 2003; 133: 486-94.
3. Berwick M, Schantz S. Chemoprevention of aerodigestive cancer. Cancer Metastasis Rev 1997; 16: 329-47.
4. Tamoto E, Tada M, Murakawa K et al. Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer. Clin Cancer Res 2004; 10: 3629-38.
5. Daigo Y, Nakamura Y. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg 2008; 56: 43-53.
6. Kikuchi T, Daigo Y, Katagiri T et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003; 22: 2192-205.
7. Kakiuchi S, Daigo Y, Tsunoda T et al. Genome-wide analysis of organpreferential metastasis of human small cell lung cancer in mice. Mol Cancer Res 2003; 1: 485-99.
8. Kakiuchi S, Daigo Y, Ishikawa N et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004; 13: 3029-43.
9. Kikuchi T, Daigo Y, Ishikawa N et al. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol 2006; 28: 799-805.
10. Taniwaki M, Daigo Y, Ishikawa N et al. Gene expression profiles of smallcell lung cancers: molecular signatures of lung cancer. Int J Oncol 2006; 29: 567-75.
11. Yamabuki T, Daigo Y, Kato T et al. Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol 2006; 28: 1375-84.
12. Suzuki C, Daigo Y, Kikuchi T et al. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res 2003; 63: 7038-41.
13. Kato T, Daigo Y, Hayama S et al. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res 2005; 65: 5638-46.
14. Furukawa C, Daigo Y, Ishikawa N et al. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res 2005; 65: 7102-10.
15. Suzuki C, Daigo Y, Ishikawa N et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res 2005; 65: 11314-25.
16. Ishikawa N, Daigo Y, Takano A et al. Characterization of SEZ6L2 cellsurface protein as a novel prognostic marker for lung cancer. Cancer Sci 2006; 97: 737-45.
17. Takahashi K, Furukawa C, Takano A et al. The neuromedin u-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res 2006; 66: 9408-19.
18. Hayama S, Daigo Y, Kato T et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 2006; 66: 10339-48.
19. Kato T, Hayama S, Yamabuki Y et al. Increased expression of IGF-II mRNAbinding protein 1 is associated with the tumor progression in patients with lung cancer. Clin Cancer Res 2007; 13: 434-42.
20. Suzuki C, Takahashi K, Hayama S et al. Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol Cancer Ther 2007; 6: 542-51.
21. Hayama S, Daigo Y, Yamabuki T et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res 2007; 67: 4113-22.
22. Taniwaki M, Takano A, Ishikawa N et al. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res 2007; 13: 6624-31.
23. Mano Y, Takahashi K, Ishikawa N et al. Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. Cancer Sci 2007; 98: 1902-13.
24. Kato T, Sato N, Hayama S et al. Activation of holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res 2007; 67: 8544-53.
25. Kato T, Sato N, Takano A et al. Activation of placenta specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. Clin Cancer Res 2008; 14: 2363-70.
26. Dunleavy EM, Roche D, Tagami H et al. HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell 2009; 137: 485-97.
27. Hirata D, Yamabuki T, Ito T et al. Involvement of epithelial cell transforming sequence 2 (ECT2) oncoantigen in lung and esophageal cancer progression. Clin Cancer Res 2009; 15: 256-66.
28. Sato N, Koinuma J, Fujita M et al. Activation of WD repeat and high-mobility group box DNA binding protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer Res 2010; 16: 226-39.
29. Sato N, Koinuma J, Ito T et al. Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis. Genes Chromosom Cancer 2010; 49: 353-67.
30. Nguyen MH, Koinuma J, Ueda K et al. Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis. Cancer Res 2010; 70: 5337-47.
31. Aragaki M, Takahashi K, Akiyama H et al. Characterization of a cleavage stimulation factor, 3' pre-RNA, Subunit 2, 64kDa (CSTF2) as a therapeutic target for lung cancer. Clin Cancer Res 2011; 17: 5889-900.
32. Masuda K, Takano A, Oshita H et al. Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer. Clin Cancer Res 2011; 17: 7712-22.
33. Ishikawa N, Daigo Y, Yasui W et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004; 10: 8363-70.
34. Ishikawa N, Daigo Y, Takano A et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005; 65: 9176-84.
35. Yamabuki T, Takano A, Hayama S et al. Dickkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007; 67: 2517-25.
36. Ishikawa N, Takano A, Yasui W et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007; 67: 11601-11.
37. Takano A, Ishikawa N, Nishino R et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009; 69: 6694-703.
38. Sato N, Yamabuki T, Takano A et al. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res 2010; 70: 5326-36.
39. Nishino R, Takano A, Oshita H et al. Identification of Epstein-Barr virusinduced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res 2011; 17: 6272-86.
40. Suda T, Tsunoda T, Daigo Y et al. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007; 98: 1803-8.
41. Mizukami Y, Kono K, Daigo Y et al. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008; 99: 1448-54.
42. Harao M, Hirata S, Irie A et al. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer 2008; 123: 2616-25.
43. Kono K, Mizukami Y, Daigo Y et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009; 100: 1502-9.
44. Tomita Y, Imai K, Senju S et al. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T lymphocytes reactive to tumor cells. Cancer Sci 2011; 102: 697-705.
45. Williams JM, Chen GC, Rest RF, Zhu L. Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth. Mol Microbiol 1998; 27: 171-86.
46. Chun H-K, Chung K-S, Kim H-C et al. OIP5 is a highly expressed potential therapeutic target for colorectal and gastric cancers. BMB Rep 2010; 43: 349-54.
47. Nakamura Y, Tanaka F, Nagahara H et al. Opa interacting protein 5 (OIP5) is a novel cancer-testis specific gene in gastric cancer. Ann Surg Oncol 2007; 14: 885-92.
48. Yuryev A, Wennogle LP. Novel raf kinase protein-protein interactions found by an exhaustive yeast two-hybrid analysis. Genomics 2003; 81: 112-25.
49. Naetar N, Hutter S, Dorner D et al. LAP2alpha-binding protein LINT-25 is a novel chromatin-associated protein involved in cell cycle exit. J Cell Sci 2007; 120: 737-47.
50. Fujita Y, Hayashi T, Kiyomitsu T et al. Priming of centromere for CENP-A recruitment by human hMis18alpha, hMis18beta, and M18BP1. Dev Cell 2007; 12: 17-30.